MediciNova Announces Management Appointment

MediciNova Announces Management Appointment

Appointment of Chief Financial Officer

SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a
biopharmaceutical company that is publicly traded on the NASDAQ Global Market
(Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:
4875), today announced the appointment of Esther van den Boom as Chief
Financial Officer.

Ms. van den Boom is owner of van den Boom & Associates, LLC (formerly Mead van
den Boom & Associates), an accounting services firm that provides accounting
and finance services to public and private companies. She has experience
working with public companies both in the biotechnology and technology
industries and assisting such companies with complex accounting and auditing
matters. Prior to starting van den Boom & Associates, Ms. van den Boom spent
nine years with Ernst & Young LLP as a Senior Manager in their audit practice
where she assisted public and private biotechnology companies. Ms. van den
Boom received a B.A. in Economics from University of California, San Diego and
a M.S. in Accountancy from San Diego State University and is a licensed CPA.

"I am very pleased MediciNova has been able to add Ms. van den Boom to our
senior management team. She completes our senior management team and positions
us very well to take advantage of our valuable product development
opportunities," commented Yuichi Iwaki M.D., Ph.D, MediciNova's President and
Chief Executive Officer. Dr. Iwaki added, "Ms. van den Boom's extensive
financial experience will be of great value to us as we further our
development collaborations domestically and globally."

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet medical needs with a commercial focus on the U.S.
market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for
neurological disorders, MN-221 for the treatment of acute exacerbations of
asthma, and MN-001 for NASH. MN-166 is being developed in multiple
indications, largely through investigator-sponsored trials and outside
funding. MediciNova is engaged in strategic partnering and consortium funding
discussions to support further development of its programs. For more
information on MediciNova, Inc., please visit

Statements in this press release that are not historical in nature constitute
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, without limitation, statements regarding our clinical
development strategies and the implication that the Company will have the
ability to execute on its priorities. These forward-looking statements may be
preceded by, followed by or otherwise include the words "believes," "expects,"
"anticipates," "intends," "estimates," "projects," "can," "could," "may,"
"will," "would," or similar expressions. These forward-looking statements
involve a number of risks and uncertainties that may cause actual results or
events to differ materially from those expressed or implied by such
forward-looking statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these forward-looking
statements, include, but are not limited to, risks of obtaining future partner
or grant funding for development of MN-166, MN-221, and MN-001 and risks of
raising sufficient capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties inherent in
clinical trials, including the potential cost, expected timing and risks
associated with clinical trials designed to meet FDA guidance and the
viability of further development considering these factors, product
development and commercialization risks, the uncertainty of whether the
results of clinical trials will be predictive of results in later stages of
product development, the risk of delays or failure to obtain or maintain
regulatory approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual property rights
in product candidates and the ability to defend and enforce such intellectual
property rights, the risk of failure of the third parties upon whom MediciNova
relies to conduct its clinical trials and manufacture its product candidates
to perform as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical trials or
significant issues regarding the adequacy of clinical trial designs or the
execution of clinical trials, and the timing of expected filings with the
regulatory authorities, MediciNova's collaborations with third parties, the
availability of funds to complete product development plans and MediciNova's
ability to obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties described in
MediciNova's filings with the Securities and Exchange Commission, including
its annual report on Form 10-K for the year ended December 31, 2013 and its
subsequent periodic reports on Forms 10-Q and 8-K.Undue reliance should not
be placed on these forward-looking statements, which speak only as of the date
hereof. MediciNova disclaims any intent or obligation to revise or update
these forward-looking statements.

         Geoff O'Brien
         Vice President
         MediciNova, Inc.

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.